02/14/17

Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with JanssenRead More

01/12/17

Ablexis Announces Perpetual License of the AlivaMab Mouse to Tri-Institutional Therapeutics Discovery InstituteRead More

Developing a Next-Generation Platform for Antibody Drug Discovery - Innovative, genetically engineered mice will serve as a world-class platform for the discovery of human therapeutic antibodies.

Highly sought after by biotechnology and pharmaceutical companies, transgenic mice still offer the most productive platform for successful human antibody drug discovery and development. Ablexis’ innovative transgenic mouse platform provides the foundation for the efficient discovery and development of the next wave of therapeutic antibodies to treat human diseases.

Learn More